Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...
ALT-B4 is Alteogen's proprietary human recombinant hyaluronidase enzyme developed utilizing HybrozymeTM technology. ALT-B4 can enable the large volume subcutaneous administration of drugs that are ...
Alteogen Inc. said that it has entered into an exclusive license agreement with Daiichi Sankyo (DSKYF.PK). As per the terms of the ...
After chemotherapy failure, if the cancer is also resistant to endocrine therapy, patients face a double obstacle: few ...
The two companies will use ALT-B4 to develop a subcutaneous version of the antibody-drug conjugate (ADC) cancer treatment ...
Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...
Anti-HER2 antibody-drug conjugates (ADCs) have proven effective in multiple tumor types. However, between 64% and 85% of HER2+ breast and gastric cancer patients retain HER2 expression after treatment ...
New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has ...
The "Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering. Antibody drug conjugates ...
In a move aimed at providing relief to cancer patients, the National Pharmaceutical Pricing Authority (NPPA) has directed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback